Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Cancer Res. 2008 Aug 1;68(15):6387–6395. doi: 10.1158/0008-5472.CAN-08-0538

Figure 6.

Figure 6

Nuclear 4ICD expression predicts patient response to tamoxifen. A, Example of primary breast tumor staining negative and B, positive for nuclear 4ICD by immunohistochemistry. C, Kaplan-Meier survival curves for tamoxifen treated ER/PgR(+) patients by presence or absence of nuclear 4ICD tumor expression. Statistical analysis requires at least one failure in each group. None of the patients with nuclear 4ICD (n = 17) failed tamoxifen therapy with 14 years of follow-up.